AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

BioMidwest

Updated: Amgen Co-Founds Fund to Help Conejo Valley Shooting Victims; Donates to Wildfire Victims

The fund will be administered through the Ventura County Community Foundation. Officials indicate that 100 percent of the funds will go to help victims’ families. The Foundation is calling for additional donations.

November 8, 2018

3 min read

Mark Terry

Genetown

15 Massachusetts Life Science Companies That Spend the Most on R&D

Boston Business Journal recently created a list of 15 Massachusetts life science companies that in their third-quarter reports, allocated the highest percentage of total costs to research and development. Here’s a look.

November 8, 2018

4 min read

Mark Terry

Business

Biogen Ups Investment in Biosimilar Drug Maker Samsung Bioepis by $700 Million

Cambridge, Mass.-based Biogen exercised its option to acquire additional shares of South Korea’s Samsung Bioepis. Samsung Bioepis focuses on developing biosimilar drugs and is a joint venture between Samsung Biologics and Biogen formed in 2012.

November 7, 2018

3 min read

Mark Terry

Why Bristol-Myers' Future is Highly Dependent on T

FDA

BMS’ Empliciti Garners a New FDA Indication for Multiple Myeloma

Joseph Eid, head of medical at BMS, said Empliciti in combination with pomalidomide and dexamethasone has provided proof that the medication can extend the time a patient can live without the worsening of his or her disease.

November 7, 2018

3 min read

Alex Keown

Business

AbbVie Follows Trend of Big Pharma Setting Office-Labs in Biotech Clusters

In what appears to be a trend, big pharma company AbbVie is leasing 479,000 square feet of space inBioMed Realty’s Gateway of Pacific project in South San Francisco.

November 2, 2018

3 min read

Mark Terry

Business

Early November Brings More Quarterly Reports

Biopharma companies set to release financial reports next week have reported positive news in recent months.

November 1, 2018

3 min read

Alex Keown

Business

Roche and AbbVie Push Towards First-Line CLL Treatment

A study evaluated fixed-duration the two companies’ Venclexta/Venclyxto (venetoclax) in combination with Genentech’s Gazyva/Gazyvaro (obinutuzumab) in patients with previously untreated chronic lymphocytic leukemia (CLL) and co-existing medical conditions.

November 1, 2018

3 min read

Mark Terry

FDA

FDA Approves Humira Biosimilar That Won’t Be Available Until 2023

The U.S. Food and Drug Administration (FDA) gave the green light to Hyrimoz, a biosimilar to AbbVie’s blockbuster drug Humira, five years ahead of the time it can be launched in U.S. markets.

November 1, 2018

2 min read

Alex Keown